Piqray (Alpelisib)
- Medicine Name: Piqray
- Generic Name: Alpelisib
- Dosage Form & Strength: Tablets: 50 mg, 150 mg, & 200 mg
- Manufactured By: Novartis
Piqray is a kinase inhibitor used along with medicinal product named Fulvestrant for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer.
Recommended Dosage: The recommended dose is 300 mg (2×150 mg film-coated tablets) taken orally, once daily, with food, at approximately the same time each day. Continue treatment until the disease is progressive or unacceptable toxicity occurs.
Swallow the tablets of Piqray whole (do not chew, split or crush tablets prior to swallowing). Do not ingest Piqray tablets if it is broken, cracked, or otherwise not intact. If a dose of Piqray is missed, take it with food within 9 hours after the time it is typically taken. After beyond 9 hours, skip the dose for that particular day. The next day, take your dose at the usual time. If the patient vomits after taking your tablet, the patient should avoid taking an additional dose on that day, and to resume the dosing schedule the very next day at the usual time.
When given with Piqray, the recommended fulvestrant dose is 500 mg administered on Days 1’st, 15’th, & 29’th, and once monthly thereafter.
- Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can appear in patients treated with alpelisib tablets. Severe hypersensitivity reactions were manifested by symptoms, including, but not limited to, rash, fever dyspnea, flushing, or tachycardia. Interrupt alpelisib therapy in severe hypersensitivity.
- Severe cutaneous adverse reactions (SCARs), including toxic epidermal necrolysis (TEN), Stevens-Johnson Syndrome (SJS), erythema multiforme (EM), and drug reaction with eosinophilia and systemic symptoms (DRESS) can emerge in patients treated with alpelisib. If signs/symptoms of SCARs occur, Consult with a dermatologist.
- Severe hyperglycemia, in a few cases associated with hyperglycemic hyperosmolar nonketotic syndrome (HHNKS) or ketoacidosis, has occurred in patients treated with piqray 200 mg or with any other strength. Fatal cases of ketoacidosis have appeared in the postmarketing setting.
- Prior to initiating treatment with Alpelisib, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. After initiating treatment with Alpelisib, monitor fasting glucose (FPG or fasting blood glucose) at least once every week for the first two weeks, then at least once every four weeks.
- Severe pneumonitis, including interstitial lung disease and acute interstitial pneumonitis, can occur in patients treated with Alpelisib. Pneumonitis was reported in patients treated with Alpelisib. Permanently discontinue this therapy in all patients with confirmed pneumonitis.
- Severe diarrhea, resulting in dehydration and in a few cases in acute kidney injury, can emerge in patients treated with alpelisib 300 mg. Monitor patients for diarrhea and additional signs/symptoms of colitis, such as mucus or blood in stool and abdominal pain. Patients should start antidiarrheal treatment, increase oral fluids, and notify their health specialist if diarrhea occurs while taking alpelisib.
- Depending on findings and its mechanism of action, alpelisib can be responsible for causing fetal harm if administered to a pregnant woman. Females of reproductive age should use effective contraception during treatment with alpelisib and for 7 days after the last dose. Male patients with female partners of reproductive age should use condoms and effective contraception during treatment with alpelisib and for 7 days after the last dose.
What documents are required to import PIQRAY to India?
PIQRAY (Alpelisib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation are needed in order to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Proof of Identity (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the valid receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is PIQRAY available in India?
PIQRAY (alpelisib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network (IPN) is a facilitator providing input
- On availability of Piqray in India (Mumbai, Pune, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, and Bangalore etc.)
- Medicine Price.
- Finding Reliable and Genuine source from USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
PIQRAY can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of PIQRAY (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Piqray tablets price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network (IPN) is able to source the PIQRAY (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Piqray®?
Alpelisib is Generic Name for the trade name drug Piqray®.
What is the Manufacturer Name of Piqray®?
Piqray® is manufactured by Novartis Pharmaceuticals Corporation.
Is Piqray® approved by the FDA?
Yes, Piqray is approved by the FDA. Date of first approval: May 24, 2019.
What is the dosage and form of Piqray® supplied?
Piqray® is supplied as Tablets: 50 mg, 150 mg, & 200 mg for oral administration.
What are the most common side effects due to Piqray®?
Most common side effects due to Piqray® include: rash, decreased appetite, weight loss, nausea, mouth sores, hair loss, tiredness/weakness, vomiting, and changes in certain blood tests.
How much does Alpelisib cost in India?
The alpelisib cost in India is sensibly reasonable. In order to procure this breast cancer medicine authentically, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
Where can I get Piqray at the best Price?
Order Piqray at a discount price today. Kindly dial our TOLL-FREE: 1800-889-1064, or WhatsApp: +91-9310090915. We’re committed to providing you with the best service and Piqray price. That is why we’ll match the price of any of the other suppliers/distributors who require an authentic prescription.
What are the storage conditions of Piqray®?
Store Piqray Tablets at 20-25°C (68-77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Is it safe to buy Piqray® online in India?
Yes, You can buy Piqray online in India authentically from https://www.indianpharmanetwork.in/ if Piqray has not been approved or is not available in your home country.
Is Indian Pharma Network (IPN) certified by WHO-GDP & ISO 9001 : 2008 authorities?
Yes, We’re certified from the top-most authorities named WHO-GDP & ISO 9001:2008. We’re legitimate and most authentic. We can help you to get this medicinal product at the lowest affordable prices.
What are the Highlights of prescribing information for Piqray®?
Click Here to download full piqray prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.